Grutters JPC, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruysscher D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation. Pharmacoeconomics. 2013;31:111–23. https://doi.org/10.1007/s40273-012-0015-4.
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
Ramaekers BLT, Joore MA, Grutters JPC. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16:855–62. https://doi.org/10.1016/J.JVAL.2013.02.013.
Espinoza MA, Sculpher MJ, Manca A, Basu A. Analysing heterogeneity to support decision making. In: Encyclopedia of Health Economics. Elsevier; 2004. p. 71–6.
Varadhan R, Seeger JD, et al. Estimation and reporting of heterogeneity of treatment effects. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a protocol for observational comparative effectiveness research: a user’s guide. Rockville: Agency for Healthcare Research and Quality; 2013.
Dahan M, Scemama C, Porcher R, Biau DJ. Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature. BMC Med Res Methodol. 2018;18:1–11. https://doi.org/10.1186/S12874-017-0466-6/TABLES/5.
Espinoza MA, Manca A, Claxton K, Sculpher MJ. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Mak. 2014;34:951–64. https://doi.org/10.1177/0272989X14538705.
Palmer S, Raftery J. Opportunity cost. BMJ. 1999;318:1551. https://doi.org/10.1136/bmj.318.7197.1551.
Article CAS PubMed PubMed Central Google Scholar
Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25(11):540–2. https://doi.org/10.1001/jama.2016.11237.
Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics. 2011;29:297–314. https://doi.org/10.2165/11584630-000000000-00000.
Ramaekers B, Grutters JJM. Acknowledging patient heterogeneity in health technology assessment. OA Epidemiol. 2014;2(1):3.
Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ. Patient variability seldom assessed in cost-effectiveness studies. Med Decis Making. 2018;38:487–94. https://doi.org/10.1177/0272989X17746989.
Article PubMed PubMed Central Google Scholar
Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25:540–2.
Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22:377–82. https://doi.org/10.1016/j.jval.2018.10.006.
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275–83.
Drummond M, Schulpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–5. https://doi.org/10.1017/s0266462305050324.
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355–71.
Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349–61. https://doi.org/10.1007/s40273-015-0327-2.
Article CAS PubMed Google Scholar
Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32–44. https://doi.org/10.1097/00005650-200301000-00007.
Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ. 2001;10:317–24. https://doi.org/10.1002/hec.592.
Article CAS PubMed Google Scholar
Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. Med Decis Making. 2003;23:379–96. https://doi.org/10.1177/0272989X03256883.
Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003;22:3687–709. https://doi.org/10.1002/SIM.1586.
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–310. https://doi.org/10.1002/hec.1148.
Heeg BMS, Damen J, Buskens E, Caleo S, De Charro F, Van Hout BA. Modelling approaches: the case of schizophrenia. Pharmacoeconomics. 2008;26(8):633–48. https://doi.org/10.2165/00019053-200826080-00002.
Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30. https://doi.org/10.1002/hec.678.
Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13:461–75. https://doi.org/10.1002/hec.843.
Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14:1217–29. https://doi.org/10.1002/hec.1008.
Drummond M. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics. 2007;25:807–16. https://doi.org/10.2165/00019053-200725100-00001.
Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009;47(7 Suppl 1):S14–20. https://doi.org/10.1097/MLR.0b013e3181a31971.
Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.
Coyle D, Buxton MJ, O’Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 2003;12:421–7. https://doi.org/10.1002/hec.788.
Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Mak. 2007;27:112–27. https://doi.org/10.1177/0272989X06297393.
Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799–806.
Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, Crown W. Machine learning methods in health economics and outcomes research—the PALISADE checklist: a good practices report of an ISPOR task force. Value Health. 2022;25:1063–80. https://doi.org/10.1016/J.JVAL.2022.03.022.
Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, Willke R, Love TR, Mattingly TJ, Perfetto EM. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26:28–38. https://doi.org/10.1016/j.jval.2022.04.1738.
Comments (0)